Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Sichuan Kelun-Biotech Biopharmaceutical Co: Clinical Trials & FDA Approval Profile

Sichuan Kelun-Biotech Biopharmaceutical Co (Global / Institutional) sponsors 41 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 35 active protocols (20 recruiting now), 4 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)4.9%
Median Closed Enrollment vs National (145 pts)295 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Sichuan Kelun-Biotech Biopharmaceutical Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)41
Active Pipeline (Recruiting Now)35 (20)
Completed vs Stopped Early4 / 2 (4.9%)
Median Closed Actual Enrollment295 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Sichuan Kelun-Biotech Biopharmaceutical Co
Hospital Research SiteLocationShared Protocols
Sun Yat-sen University Cancer CenterGuangzhou, Guangdong10
Jiangsu Province HospitalNanjing, Jiangsu7
The first affiliated hospital of Zhengzhou UniversityZhengzhou, Henan6

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07564466A Study of SKB571 in Participants With Gastrointestinal TumorsPhase IIRECRUITING
NCT07622186A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)Phase IIRECRUITING
NCT07019675A Study of SKB518 in Patients With Lung CancerPhase IIRECRUITING
NCT07700667SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaPhase IIRECRUITING
NCT06711900A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1Phase IIIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Sichuan Kelun-Biotech Biopharmaceutical Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI